DE68929382D1 - Liposomen - Google Patents

Liposomen

Info

Publication number
DE68929382D1
DE68929382D1 DE68929382T DE68929382T DE68929382D1 DE 68929382 D1 DE68929382 D1 DE 68929382D1 DE 68929382 T DE68929382 T DE 68929382T DE 68929382 T DE68929382 T DE 68929382T DE 68929382 D1 DE68929382 D1 DE 68929382D1
Authority
DE
Germany
Prior art keywords
liposomes
external surface
intravenous administration
covalently bound
serum half
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68929382T
Other languages
English (en)
Other versions
DE68929382T2 (de
Inventor
Derek Fisher
Gillian Elizabeth Francis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polymasc Pharmaceuticals PLC
Original Assignee
Polymasc Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10645513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68929382(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polymasc Pharmaceuticals PLC filed Critical Polymasc Pharmaceuticals PLC
Publication of DE68929382D1 publication Critical patent/DE68929382D1/de
Application granted granted Critical
Publication of DE68929382T2 publication Critical patent/DE68929382T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE68929382T 1988-10-20 1989-10-20 Liposomen Expired - Fee Related DE68929382T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888824593A GB8824593D0 (en) 1988-10-20 1988-10-20 Liposomes

Publications (2)

Publication Number Publication Date
DE68929382D1 true DE68929382D1 (de) 2002-04-25
DE68929382T2 DE68929382T2 (de) 2002-10-17

Family

ID=10645513

Family Applications (2)

Application Number Title Priority Date Filing Date
DE68929382T Expired - Fee Related DE68929382T2 (de) 1988-10-20 1989-10-20 Liposomen
DE68915001T Expired - Fee Related DE68915001T2 (de) 1988-10-20 1989-10-20 Liposome.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE68915001T Expired - Fee Related DE68915001T2 (de) 1988-10-20 1989-10-20 Liposome.

Country Status (7)

Country Link
US (1) US20030152618A1 (de)
EP (2) EP0445131B1 (de)
JP (1) JP2948246B2 (de)
AT (2) ATE214594T1 (de)
DE (2) DE68929382T2 (de)
GB (1) GB8824593D0 (de)
WO (1) WO1990004384A1 (de)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
EP0664713B1 (de) * 1992-10-14 2000-01-19 Nycomed Imaging As Therapeutische und diagnostische bilderzeugungzusammensetzung und verfahren zur herstellung
WO1994009056A1 (en) * 1992-10-14 1994-04-28 Sterling Winthrop Inc. Chelating polymers
US5817292A (en) * 1992-10-14 1998-10-06 Nycomed Imaging As MR imaging compositions and methods
JP3351476B2 (ja) * 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
GB9317618D0 (en) * 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5540935A (en) * 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
US5463066A (en) * 1993-12-06 1995-10-31 Nof Corporation Phospholipid derivative and reactive vesicle-forming agent
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
GB9509016D0 (en) * 1995-05-03 1995-06-21 Royal Free Hosp School Med Tissue entrapment
US6673364B1 (en) 1995-06-07 2004-01-06 The University Of British Columbia Liposome having an exchangeable component
DE69800640T2 (de) * 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc L Pegylationsverfahren
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US6083923A (en) * 1997-10-31 2000-07-04 Isis Pharmaceuticals Inc. Liposomal oligonucleotide compositions for modulating RAS gene expression
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
AU751434B2 (en) * 1997-12-23 2002-08-15 Inex Pharmaceuticals Corporation Polyamide oligomers
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
AU6366599A (en) * 1998-10-29 2000-05-22 Sankyo Company Limited Liposome with lowered toxicity
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
ES2336766T3 (es) 2000-10-04 2010-04-16 Kyowa Hakko Kirin Co., Ltd. Procedimiento de recubrimiento de particulas finas con pelicula lipidica.
WO2003000707A2 (en) 2001-06-21 2003-01-03 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ566396A (en) 2001-10-09 2009-07-31 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expressions
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
DE60335469D1 (de) 2002-07-02 2011-02-03 Univ Texas Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren
AU2003267785C1 (en) 2002-09-13 2009-12-24 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
EP2272958A1 (de) 2002-09-26 2011-01-12 ISIS Pharmaceuticals, Inc. Modulierung von der Forkheadbox O1A-Expression
EP1569695B1 (de) 2002-11-13 2013-05-15 Genzyme Corporation Antisense-modulation von apolipoprotein-b-expression
DK1569695T3 (da) 2002-11-13 2013-08-05 Genzyme Corp Antisense-modulering af apolipoprotein-b-ekspression
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US7960350B2 (en) 2003-10-24 2011-06-14 Ader Enterprises, Inc. Composition and method for the treatment of eye disease
EP1735009A4 (de) 2004-03-12 2011-03-30 Alnylam Pharmaceuticals Inc Irna mittel targeting vegf
EP1861072A2 (de) * 2005-03-14 2007-12-05 Massachusetts Institute Of Technology Nanozellen zur diagnose und behandlung von krankheiten und störungen
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007053696A2 (en) 2005-11-01 2007-05-10 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
KR20170061189A (ko) 2006-03-31 2017-06-02 알닐람 파마슈티칼스 인코포레이티드 Ｅｇ5 유전자의 발현을 억제하는 이본쇄 리보핵산
EP2013222B1 (de) 2006-04-28 2013-02-13 Alnylam Pharmaceuticals Inc. Zusammensetzungen und verfahren zur hemmung der expression eines gens aus dem jc-virus
CN101489566B (zh) 2006-05-19 2012-04-18 阿尔尼拉姆医药品有限公司 Aha基因的RNAi调控及其治疗性应用
CA2653451C (en) 2006-05-22 2015-12-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
US8598333B2 (en) 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
EP2118118B1 (de) 2007-01-19 2017-09-27 Exiqon A/S Vermittelte zelluläre verabreichung von lna-oligonukleotiden
CA2682161A1 (en) 2007-03-29 2008-10-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from ebola virus
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
EP2617828B1 (de) 2007-12-10 2014-09-24 Alnylam Pharmaceuticals Inc. Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
KR101397407B1 (ko) 2008-03-05 2014-06-19 알닐람 파마슈티칼스 인코포레이티드 Ｅｇ5 및 ＶＥＧＦ 유전자의 발현을 억제하기 위한 조성물 및 방법
EP2105145A1 (de) 2008-03-27 2009-09-30 ETH Zürich Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
US20100003315A1 (en) 2008-07-02 2010-01-07 Willeford Kenneth L Method and Composition for the Treatment of Skin Conditions
US8252762B2 (en) 2008-08-25 2012-08-28 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP2331690B1 (de) 2008-09-02 2016-01-13 Alnylam Pharmaceuticals Inc. Zusammensetzungen und verfahren zur hemmung der expression eines mutierten egfr-gens
EP3109321B1 (de) 2008-09-25 2019-05-01 Alnylam Pharmaceuticals, Inc. Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression
IL281434B2 (en) 2008-10-20 2023-09-01 Alnylam Pharmaceuticals Inc Compounds and methods for inhibiting transthyretin expression
CA2746514C (en) 2008-12-10 2018-11-27 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
US20120041051A1 (en) 2009-02-26 2012-02-16 Kevin Fitzgerald Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
WO2010107990A1 (en) * 2009-03-19 2010-09-23 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
WO2010143969A2 (en) * 2009-06-08 2010-12-16 Epitarget As Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylethanolamine
DE102009031274A1 (de) * 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
AP3574A (en) 2009-08-14 2016-02-08 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
WO2011116256A2 (en) * 2010-03-18 2011-09-22 The Regents Of The University Of Michigan Multiphase microarrays and uses thereof
EP3329924B1 (de) 2010-03-29 2021-05-05 Alnylam Pharmaceuticals, Inc. Dsrna-therapie für durch transthyretin (ttr) vermittelte augenamyloidose
JP2013523162A (ja) 2010-04-06 2013-06-17 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｃｄ２７４／ｐｄ−ｌ１遺伝子の発現を阻害するための組成物および方法
KR101198715B1 (ko) * 2010-05-14 2012-11-13 한국생명공학연구원 핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법
CA2801066C (en) 2010-06-02 2021-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
US9339513B2 (en) 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP2649182A4 (de) 2010-12-10 2015-05-06 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
EP2648763A4 (de) 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
MX365647B (es) 2011-02-02 2019-06-10 Excaliard Pharmaceuticals Inc El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.
MX343008B (es) 2011-03-29 2016-10-21 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
JP6662566B2 (ja) 2011-06-02 2020-03-11 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ エキソビボ組織培養システムのための方法および使用
WO2012177949A2 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of protein c (proc) genes
US20140275211A1 (en) 2011-06-21 2014-09-18 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
KR20230084331A (ko) 2011-06-21 2023-06-12 알닐람 파마슈티칼스 인코포레이티드 아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
EP3597750B1 (de) 2011-06-23 2022-05-04 Alnylam Pharmaceuticals, Inc. Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
WO2013003112A1 (en) 2011-06-27 2013-01-03 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
WO2013019857A2 (en) 2011-08-01 2013-02-07 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
DK2941269T3 (da) 2013-01-07 2021-01-11 Mucosal Vaccine Tech Llc Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner
EP3708184A1 (de) 2013-03-27 2020-09-16 The General Hospital Corporation Verfahren und mittel zur behandlung von morbus alzheimer
EP2994167B1 (de) 2013-05-06 2020-05-06 Alnylam Pharmaceuticals, Inc. Dosierungen und verfahren zur abgabe von lipidformulierten nukleinsäuremolekülen
TWI669393B (zh) 2013-10-02 2019-08-21 艾爾妮蘭製藥公司 抑制ｌｅｃｔ２基因表現之組合物及方法
EP3052628B1 (de) 2013-10-04 2020-02-26 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der alas1-genexpression
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CA2970795A1 (en) 2014-12-18 2016-06-23 Alnylam Pharmaceuticals, Inc. Reversir compounds
KR20240005184A (ko) 2014-12-31 2024-01-11 랜티우스 메디컬 이메징, 인크. 지질-캡슐화된 기체 마이크로스피어 조성물 및 관련 방법
CA2974369A1 (en) 2015-01-20 2016-07-28 The Children's Medical Center Corporation Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
CN108024535A (zh) 2015-07-02 2018-05-11 大塚制药株式会社 冻干药物组合物
WO2017015109A1 (en) 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
WO2017048843A1 (en) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the alas1 gene
MX2018013409A (es) 2016-05-04 2019-07-08 Lantheus Medical Imaging Inc Métodos y dispositivos para la preparación de agentes de contraste de ultrasonido.
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
CA3061752A1 (en) 2017-07-06 2019-01-10 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of alpha-enac and methods of use
CA3071755A1 (en) 2017-08-03 2019-02-07 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
EP3837367A1 (de) 2018-08-16 2021-06-23 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
EP3887516A1 (de) 2018-11-29 2021-10-06 Flagship Pioneering Innovations V, Inc. Verfahren zur modulation von rna
MX2022002689A (es) 2019-09-03 2022-04-07 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen de quimiotaxina derivada de celulas de leucocitos 2 (lect2).
WO2021067747A1 (en) 2019-10-04 2021-04-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
EP4051796A1 (de) 2019-11-01 2022-09-07 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
TW202140786A (zh) 2020-02-10 2021-11-01 美商艾爾妮蘭製藥公司 用於靜默ｖｅｇｆ－ａ表現之組合物及方法
WO2021202443A2 (en) 2020-03-30 2021-10-07 Alnylam Pharmaceucticals, Inc. Compositions and methods for silencing dnajc15 gene expression
MX2022012493A (es) 2020-04-06 2022-10-27 Alnylam Pharmaceuticals Inc Composiciones y metodos para el silenciamiento de la expresion de miocilina (myoc).
AU2021251754A1 (en) 2020-04-07 2022-11-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing SCN9A expression
WO2021237097A1 (en) 2020-05-21 2021-11-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
EP4367237A2 (de) 2021-07-09 2024-05-15 Alnylam Pharmaceuticals, Inc. Bis-rnai-verbindungen zur zns-verabreichung
WO2024059165A1 (en) 2022-09-15 2024-03-21 Alnylam Pharmaceuticals, Inc. 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4897308A (en) * 1975-06-30 1990-01-30 L'oreal Compositions comprising aqueous dispersions of lipid spheres
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4708933A (en) * 1984-06-12 1987-11-24 Leaf Huang Immunoliposome assay-methods and products
US4707441A (en) * 1984-08-06 1987-11-17 Technicon Instruments Corp. Binding assays in automated apparatus with liposome compatible surfactants
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time

Also Published As

Publication number Publication date
EP0572049A3 (en) 1994-02-23
DE68915001T2 (de) 1994-08-04
JPH04501117A (ja) 1992-02-27
WO1990004384A1 (en) 1990-05-03
US20030152618A1 (en) 2003-08-14
EP0572049B1 (de) 2002-03-20
DE68915001D1 (en) 1994-06-01
JP2948246B2 (ja) 1999-09-13
DE68929382T2 (de) 2002-10-17
ATE214594T1 (de) 2002-04-15
EP0445131B1 (de) 1994-04-27
EP0445131A1 (de) 1991-09-11
EP0572049A2 (de) 1993-12-01
GB8824593D0 (en) 1988-11-23
ATE104846T1 (de) 1994-05-15

Similar Documents

Publication Publication Date Title
DE68929382T2 (de) Liposomen
EP0526700A3 (de)
GB2238962B (en) Dual source intravenous adminstration set having an intravenous pump
IT8521451A0 (it) Coniugati glicoproteici adattivita' immunogenica trivalente.
DE69022490T2 (de) Gurtschnalle mit zwei Steckzungen.
DE3853507T2 (de) Ablenkmagnet.
NO881273D0 (no) Molekylaere markoerer.
FI872369A0 (fi) Foerfarande foer bestaemning av en hiss' position samt en pulsvaoningsraeknare.
FI884745A0 (fi) Foerfarande foer styrning av en hiss' noedbroms samt en noedbroms.
DE68905583D1 (de) Druckkassette mit nicht-divergentem elektrostatischem feld.
DE3874359D1 (de) Flammwidrige polyamidharzzubereitung.
IT1226123B (it) Turbopompa molecolare.
FI893616A (fi) Ny anvaendning foer 5-hetero-aryl- eller 5-arylsubstituerade imidazo/2,1-a/ isokinoliner.
DK205189D0 (da) Polyketonpolymerer
IT8820808A0 (it) Poliammine parzialmente sostituite con 4,6 bis[ n,n bis(2,2,6,6 tetrametil 4piperidil)ammino]-1,3,5-triazin-2-il.
DE58907235D1 (de) Polymerisatmischung.
DE68921231D1 (de) Pfahlrammanlage.
DE68924645T2 (de) Verabreichungsmaschine.
FI860127A (fi) Nya 12-amino-pyridazino/4',5':3,4/ pyrrolo/2,1-a/isokinoliner, foerfarande foer deras framstaellning och anvaendning.
DE3887446D1 (de) Polyketonpolymere.
IT8720256A0 (it) Complessi di b- ciclodestrina adattivita' antimicotica.
FI882916A (fi) Skjutled i en hiss.
DE3884300T2 (de) Magnetische Polymerzusammensetzungen.
IT1226838B (it) Macinacaffe'.
FI880322A0 (fi) Foerfarande och anordning foer styrning av en hiss i sidoriktning.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee